Fg-m131
Preclinical
Fg-m131 is one of 6 therapeutic programs targeting PTCL. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
5 competitors in PTCL
#DrugCompanyPhaseTrials
1Opzelura
DDizal Pharmaceuticals
Phase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Mitoxantrone Hydrochloride Liposome
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 2
Zeprumetostat
SSun Yat-sen University
Phase 2
BR101801
Boryung Pharmaceutical Co., LtdPhase 2
Fg-m131
FFutureGen Biopharmaceutical (Beijing) Co., Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
PTCL1 trial
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FG-M131 in Patients With TRBC1-positive Relapsed/Refractory Peripheral T-cell Lymphoma
Not yet recruiting·FFutureGen Biopharmaceutical (Beijing) Co., Ltd·Preclinical·NCT07758491·110 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Fg-m131. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]